Clinical trials
catalyst calendar across sponsors →Studies where CLYM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 10 tracked-famous managers (CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Qube Research & Technologies Ltd, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, +5 more) · FINRA short interest 6.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyNCT07096843Incidence of Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: budoprutug | Primary Membranous Nephropathy | 45 | Oct 2027 | ≤ 438 d | 2026-07-16 |
| A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)NCT07564596Incidence of Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Budoprutug | Systemic Lupus Erthematosus | 30 | Sep 2027 | ≤ 407 d | 2026-08-06 |
| A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)NCT07043946Incidence of Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Budoprutug | Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19 | 24 | Aug 2027 | ≤ 377 d | 2026-03-27 |
| A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)NCT07011043Incidence of Treatment-Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Budoprutug | Systemic Lupus Erythematosus | 30 | Apr 2027 | ≤ 254 d | 2026-03-27 |
| A Phase 1 Study of CLYM116 in Normal Healthy VolunteersNCT07248865Safety and tolerability of single and multiple ascending doses of CLYM116 in healthy volunteers Incidence of treatment-emergent adverse eventsRandomized · Double-masked · Basic science | Phase 1 | Recruiting | Drug: CLYM116, Placebo | Healthy Volunteers | 48 | Jul 2026 | — | 2026-02-20 |
| A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy VolunteersNCT07090655Safety and Tolerability of Single Ascending Doses of budoprutug in Healthy ParticipantsRandomized · Double-masked · Basic science | Early Phase 1 | Completed | Drug: Budoprutug, Placebo | Healthy Volunteers | 30 | 2026-04-07actual | — | 2026-07-30 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19